Longduoduo(OTC) LDDD

Longduoduo helps people in China check for and prevent serious health problems. Its services include disease screening and therapies for heart and brain conditions. The company works with clinics and suppliers to reach patients needing early health interventions.

Products and Services

• Commission-based preventive healthcare: Sales of third-party health services, 96.4% of revenue, for people seeking early disease detection.
• Direct healthcare services: Disease screening and treatments, 3.7% of revenue, for patients at risk of heart or brain issues.
• Healthcare products: Supplies for disease prevention, targeting individuals managing chronic health risks.
• Specialized therapies: Includes blood purification, platelet-rich plasma, and nerve regulation, for patients with complex health needs.
• Relaxation and recovery therapies: Stress reduction and rehabilitation services for people recovering from illness or injury.

Growth and Expansion

• Shifted focus in June 2023 to agent sales through a Sales Agency Agreement with Inner Mongolia Honghai Health Management Co. Ltd.
• Expanded operations in major Inner Mongolia and Beijing cities via subsidiaries since 2023.
• Streamlined business through acquisitions and reorganizations to improve efficiency in 2023.
• Increased advertising and promotion to build brand presence, with tactical reductions in 2024 due to economic conditions.

What Makes Longduoduo Stand Out

Longduoduo combines direct healthcare services with commission-based sales, creating multiple revenue streams. Its focus on preventive care addresses rising demand for early disease detection in China. The company’s urban presence and agency model help it reach large populations efficiently.

Five Things You Need to Know

• Revenue was $3.32 million for nine months ended March 2025, down 42% year-over-year.
• Commission revenue made up approximately 96.5% of total revenue in the same period.
• One customer accounted for 99.9% of commission revenue, showing high concentration risk.
• Gross margin was approximately 97.5% for nine months ended March 2025, with net income of $325,775.
• Cash and cash equivalents were $1.46 million as of March 31, 2025.

Bottom Line

Longduoduo has evolved by shifting to an agency sales model and focusing on preventive healthcare. Its business now relies on a few key partners and customers, with strong gross margins but notable concentration risks.